KERI REED: Open Payments
NPI 1740939222 · LEONARDTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$736 in 34 payments from 10 companies in 2025. Trend: 2023 $113 · 2024 $236 · 2025 $736
Food & beverage: $736
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $149 |
| GENZYME CORPORATION | 7 | $142 |
| UCB, Inc. | 4 | $91 |
| ABBVIE INC. | 4 | $86 |
| Novartis Pharmaceuticals Corporation | 3 | $80 |
| Organon LLC | 4 | $61 |
| Amgen Inc. | 2 | $53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Arcutis Biotherapeutics, Inc. | 1 | $14 |
Products named: DUPIXENT, TREMFYA, Bimzelx, COSENTYX, SKYRIZI, SPEVIGO, ENBREL, VRAYLAR.
Industry payments across MD — which companies pay providers there.
